ArticleFrontiers in pharmacology2022

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.

Yamin Shu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.